Acute urinary morbidity following I-125 prostate brachytherapy

In Japan, iodine-125 (I-125) prostate brachytherapy has been legally approved since July 2003, and this method is becoming more popular. The purpose of the present study was to assess acute urinary morbidity within the first 6 months after I-125 prostate brachytherapy. A group of 130 consecutive pat...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2005-08, Vol.10 (4), p.262-268
Main Authors: Ohashi, Toshio, Yorozu, Atsunori, Toya, Kazuhito, Saito, Shiro, Momma, Tetsuo
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Brachytherapy - adverse effects
Catheters
Combined Modality Therapy
Follow-Up Studies
Humans
Iodine Radioisotopes - adverse effects
Japan
Male
Middle Aged
Morbidity
Oncology
Palladium - therapeutic use
Prostate cancer
Prostate-Specific Antigen - blood
Prostatic Neoplasms - blood
Prostatic Neoplasms - radiotherapy
Radiation
Radiation Injuries - etiology
Radiopharmaceuticals - adverse effects
Urinary Tract - radiation effects
Urination Disorders - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In Japan, iodine-125 (I-125) prostate brachytherapy has been legally approved since July 2003, and this method is becoming more popular. The purpose of the present study was to assess acute urinary morbidity within the first 6 months after I-125 prostate brachytherapy. A group of 130 consecutive patients with localized prostate cancer was treated with I-125 prostate brachytherapy between September 2003 and June 2004,either alone (monotherapy; 66 patients) or in combination with external-beam radiotherapy (combined therapy; 64 patients). Urinary morbidity was evaluated using the National Cancer Institute - Common Terminology Criteria for Adverse Events, version 3.0. During the follow-up, 111 patients (85.4%) developed some degree of urinary symptoms such as frequency, retention, dysuria, incontinence, or hematuria. Urinary frequency (73.1%) and retention (66.9%) were the most common, and showed no significant differences between the monotherapy group and combined therapy group (P = 0.352 and P = 0.630, respectively). Six patients (4.6%) required catheterization for urinary obstruction; the median time to onset was 1.5 days (range, 1-192 days). Five of these 6 patients received monotherapy and the other received combined therapy. Manifestations of acute urinary morbidity, especially frequency and retention, are relatively common but acceptable events after I-125 prostate brachytherapy.
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-005-0507-8